Johnson & Johnson (WBO:JNJ) Stock News, Headlines & Updates
Johnson & Johnson Stock News from GuruFocus
- 1
Aug 20, 2024
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
PRNewswire • 7:00am
Johnson & Johnson to Acquire V-Wave
Business Wire • 7:00am
Aug 19, 2024
Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson
GuruFocus Research • 6:00am
Aug 07, 2024
Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine
PRNewswire • 4:01pm
Aug 05, 2024
Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson
GuruFocus Research • 6:00am
Jul 30, 2024
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
PRNewswire • 6:00pm
Jul 29, 2024
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference
Business Wire • 4:00pm
Jul 26, 2024
Courts, Congress Likely to Stand in Way of J&J's Third Texas Two-Step Plan
Business Wire • 9:00am
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
Business Wire • 9:00am
Jul 23, 2024
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Business Wire • 4:00pm
Jul 22, 2024
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J's Latest Bankruptcy Plan
Business Wire • 11:00am
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
PRNewswire • 8:00am
Beyond Market Price: Uncovering Johnson & Johnson's Intrinsic Value
GuruFocus Research • 6:00am
Jul 18, 2024
Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript Highlights: Strong Sales Growth Amid Competitive Pressures
GuruFocus Research • 1:01am
Q2 2024 Johnson & Johnson Earnings Call Transcript
GuruFocus Research • 11:02pm
Jul 17, 2024
Johnson & Johnson's Oncology Strength Drives Q2 Outperformance Despite MedTech Weakness
GuruFocus Research • 12:14pm
Johnson & Johnson Q2 2024 Earnings: Adjusted EPS Beats Expectations with 10.2% Growth, Revenue Up 4.3%
GuruFocus Research • 7:31am
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
Business Wire • 6:00am
Johnson & Johnson reports Q2 2024 results
Business Wire • 6:00am
Jul 11, 2024
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
Business Wire • 7:00am
Jul 08, 2024
Johnson & Johnson: An Exploration into Its Intrinsic Value
GuruFocus Research • 6:00am
Jul 02, 2024
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
PRNewswire • 7:00am
Jun 28, 2024
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
PRNewswire • 11:00am
Jun 27, 2024
Lawyers for Johnson & Johnson's Ovarian Cancer Victims React to SCOTUS Decision in Purdue
Business Wire • 6:00pm
Jun 24, 2024
Beyond Market Price: Uncovering Johnson & Johnson's Intrinsic Value
GuruFocus Research • 6:00am
Jun 21, 2024
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
Business Wire • 7:00am
Jun 20, 2024
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
PRNewswire • 4:00pm
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme
Business Wire • 1:00pm
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
PRNewswire • 8:00am
Jun 17, 2024
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products
Business Wire • 5:00pm
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
PRNewswire • 8:00am
Jun 15, 2024
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
PRNewswire • 3:00am
Jun 14, 2024
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
PRNewswire • 8:00am
Jun 12, 2024
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson's Use of Bankruptcy Strategy
Business Wire • 2:00pm
Jun 10, 2024
Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson
GuruFocus Research • 6:00am
Jun 04, 2024
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Business Wire • 4:00pm
May 31, 2024
Johnson & Johnson Completes Acquisition of Shockwave Medical
Business Wire • 8:00am
May 28, 2024
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
Marketwired • 7:00am
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
Business Wire • 7:00am
May 27, 2024
Johnson & Johnson: An Exploration into Its Intrinsic Value
GuruFocus Research • 6:00am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news